Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-02-23
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate bintrafusp alfa monotherapy in participants
with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a
centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.